IP Library › Granted Patent US 12,383,586
Granted Patent B2
US 12,383,586 · App. 18/627,241 · Granted Aug 12, 2025

Spore-based probiotic supplementation in dogs and control of endotoxemia

Inventors: Kiran Krishnan (Saint Augustine, FL); Dale M. Kriz (Saint Augustine, FL); Thomas F. Bayne (Saint Augustine, FL)
Assignee: Novozymes A/S
A61K35/744A61K9/0053A61K35/742A61P1/14A61P31/04
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,383,586
App. No.
18/627,241
Granted
Aug 12, 2025
Kind
B2
Abstract

The present invention is directed to methods of administering a probiotic composition including Bacillus subtilis, Bacillus licheniformis , and Pediococcus acidilactici to dogs to decrease endotoxemia and improve the digestive process, and related methods.

Claims (16)

1. A method of decreasing endotoxemia in a dog comprising the steps of:

(a) providing a probiotic composition comprising Bacillus subtilis, Bacillus licheniformis , and Pediococcus acidilactici , and

(b) administering the probiotic composition to the dog in an amount effective to decrease endotoxemia in the dog.

2. The method of claim 1 , wherein said Bacillus subtilis, Bacillus licheniformis , and Pediococcus acidilactici total about 1 billion to about 10 billion CFU.

3. The method of claim 2 , wherein said CFU total is about 2.5 billion to about 5 billion CFU.

4. The method of claim 3 , wherein said Bacillus subtilis is Bacillus subtilis HU58.

5. The method of claim 2 , wherein said Bacillus subtilis is Bacillus subtilis HU58.

6. The method of claim 1 , wherein the total amount of probiotics in said probiotic composition is about 2 billion CFUs Bacillus subtilis , about 500 million to 1 billion CFUs Pediococcus acidilactici , and about 100 million CFUs of Bacillus licheniformis.

7. The method of claim 6 , wherein said Bacillus subtilis is Bacillus subtilis HU58.

8. The method of claim 1 , wherein said probiotic composition is orally administered to the dog.

9. The method of claim 8 , wherein said oral administration is for at least 30 days.

10. The method of claim 9 , wherein said Bacillus subtilis is Bacillus subtilis HU58.

11. The method of claim 8 , wherein said Bacillus subtilis is Bacillus subtilis HU58.

12. The method of claim 1 , wherein said Bacillus subtilis is Bacillus subtilis HU58.

13. The method of claim 1 , wherein said probiotic composition further comprises beef liver extract.

14. The method of claim 1 , wherein said dog exhibits dysbiosis.

Continuity (3)
Continuation 17023097 · Sep 16, 2020
Provisional Application 62900901 · Sep 16, 2019
Related Publication 20240307464A1 · Sep 19, 2024
References Cited (34)
US 20060008511A1 · Lin et al. · 2006 [cited by applicant]
US 20120052152A1 · Armentrout · 2012 [cited by applicant]
US 20120315249A1 · Olmstead · 2012 [cited by applicant]
US 20140023693A1 · Guenzburg et al. · 2014 [cited by applicant]
US 20150157670A1 · Kriz et al. · 2015 [cited by applicant]
US 20180289752A1 · Krishnan et al. · 2018 [cited by applicant]
CN 102651973A · 2012 [cited by applicant]
CN 103068254A · 2013 [cited by applicant]
CN 103764154A · 2014 [cited by applicant]
CN 104684408A · 2015 [cited by applicant]
CN 108371247A · 2018 [cited by applicant]
WO 2004080200A1 · 2004 [cited by applicant]
WO 2011069860A1 · 2011 [cited by applicant]
WO 2011075138A1 · 2011 [cited by applicant]
WO 2012170915A1 · 2012 [cited by applicant]
WO 2014020138A2 · 2014 [cited by applicant]
Anonymous, 2019, fidospore, 1-18—Tr. [cited by applicant]
Barko_2018_Journal_of_Veterinary_Internal_Medicine_32_9-25. [cited by applicant]
Bartko_2017_Pharmacological_research_125_215-223. [cited by applicant]
Biourge 1998 J. Nutrition 128(12 suppl) 2730S-2732S, 128(12 suppl). [cited by applicant]
CEAPA_2013_Best_Practice_&_Research_Clinical_Gastroenterology_27_139-155. [cited by applicant]
De Vries et al, 2013, International journal of Immunopathology and Pharmacology 26(4), 861-869. [cited by applicant]
Gallo_2016_World_journal_of_Gastroenterology_22_7186-7202. [cited by applicant]
Herstad_2010_Journal_of_small_animal_practice_51_34-38. [cited by applicant]
Jackson_1991_Lebensmittel-wissenschaft_technologie_24_289-297. [cited by applicant]
Kerns_2005_The_Canine_Digestion_Process_Whole_Dog_Journal. [cited by applicant]
Krishnan, 2017, AAPLI's nutrition guide to optimal health using principles of functional medicine and nutritional genomics, part 3, 269-286. [cited by applicant]
McFarlin et al., The American Journal of Gastroenteroloty, S657-S658, 2017. [cited by applicant]
McFarlin et al., World journal of Gastrointestinal Pathophysiology, 8(3), 117-126, 2017. [cited by applicant]
Schmitz_2016_Veterinary_medicine_and_science_2_71-94. [cited by applicant]
Van Deventer 1990 Blood 76(12) 2520-2526. [cited by applicant]
Vasanth 2015 Frontiers in immunology 6(article 409) 1-11, 409. [cited by applicant]
Wang, Journal of Hainan Medical University, 19(12)—Translation, 1781-1784, 2013. [cited by applicant]
Wang, Journal of Hainan Medical University, 19(12), 1781-1784, 2013. [cited by applicant]